GOALS OF WORK: The aim of this study was to prospectively evaluate chemotherapy-induced peripheral neuropathy (CIPN) using a patient-based instrument, the Patient Neurotoxicity Questionnaire (PNQ) and a physician-based instrument, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) in patients with advanced or metastatic breast cancer who were treated with weekly paclitaxel. MATERIALS AND METHODS: CIPN symptoms were prospectively assessed in 35 patients using the PNQ, NCI-CTC, and the Functional Assessment of Cancer Therapy (FACT)-Taxane including neurotoxicity component (Ntx) at the baseline, and 8 and 16 weeks after starting chemotherapy. RESULTS: For sensory neuropathy symptoms, the reported incidence of CIPN was significantly increased during active treatment in terms of both the PNQ and NCI-CTC assessments. In contrast, there was a notable increase of patient motor neuropathy symptoms that were elucidated only by the PNQ. The PNQ grades of CIPN were widely distributed in the patient population as compared with the NCI-CTC grades for both sensory and motor neuropathy. The sensory PNQ grade was correlated with sensory NCI-CTC grade (r = 0.58) and Ntx (r = 0.51), and the motor PNQ grade was correlated with Ntx (r = 0.57). CONCLUSIONS: The PNQ appears to be more sensitive and responsive than the NCI-CTC for CIPN; the PNQ appears to have diagnostic validity for evaluating CIPN in patients who are receiving neurotoxic chemotherapy.
GOALS OF WORK: The aim of this study was to prospectively evaluate chemotherapy-induced peripheral neuropathy (CIPN) using a patient-based instrument, the PatientNeurotoxicity Questionnaire (PNQ) and a physician-based instrument, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) in patients with advanced or metastatic breast cancer who were treated with weekly paclitaxel. MATERIALS AND METHODS: CIPN symptoms were prospectively assessed in 35 patients using the PNQ, NCI-CTC, and the Functional Assessment of Cancer Therapy (FACT)-Taxane including neurotoxicity component (Ntx) at the baseline, and 8 and 16 weeks after starting chemotherapy. RESULTS: For sensory neuropathy symptoms, the reported incidence of CIPN was significantly increased during active treatment in terms of both the PNQ and NCI-CTC assessments. In contrast, there was a notable increase of patientmotor neuropathy symptoms that were elucidated only by the PNQ. The PNQ grades of CIPN were widely distributed in the patient population as compared with the NCI-CTC grades for both sensory and motor neuropathy. The sensory PNQ grade was correlated with sensory NCI-CTC grade (r = 0.58) and Ntx (r = 0.51), and the motor PNQ grade was correlated with Ntx (r = 0.57). CONCLUSIONS: The PNQ appears to be more sensitive and responsive than the NCI-CTC for CIPN; the PNQ appears to have diagnostic validity for evaluating CIPN in patients who are receiving neurotoxic chemotherapy.
Authors: Jeff A Sloan; Lawrence Berk; Joseph Roscoe; Michael J Fisch; Edward G Shaw; Gwen Wyatt; Gary R Morrow; Amylou C Dueck Journal: J Clin Oncol Date: 2007-11-10 Impact factor: 44.544
Authors: G Fountzilas; U Dafni; M A Dimopoulos; A Koutras; D Skarlos; P Papakostas; H Gogas; D Bafaloukos; A Kalogera-Fountzila; E Samantas; E Briasoulis; D Pectasides; N Maniadakis; F Matsiakou; G Aravantinos; C Papadimitriou; M Karina; C Christodoulou; P Kosmidis; H P Kalofonos Journal: Breast Cancer Res Treat Date: 2008-05-16 Impact factor: 4.872
Authors: A D Seidman; C A Hudis; J Albanell; J Albanel; W Tong; I Tepler; V Currie; M E Moynahan; M Theodoulou; M Gollub; J Baselga; L Norton Journal: J Clin Oncol Date: 1998-10 Impact factor: 44.544
Authors: Barbara K Bennett; Susanna B Park; Cindy S-Y Lin; Michael L Friedlander; Matthew C Kiernan; David Goldstein Journal: Support Care Cancer Date: 2012-03-17 Impact factor: 3.603
Authors: Hannah C Timmins; Tiffany Li; Terry Trinh; Matthew C Kiernan; Michelle Harrison; Frances Boyle; Michael Friedlander; David Goldstein; Susanna B Park Journal: Oncologist Date: 2021-02-10
Authors: Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel Journal: Oncologist Date: 2019-10-14
Authors: Ellen M Lavoie Smith; Herbert Pang; Constance Cirrincione; Stewart Fleishman; Electra D Paskett; Tim Ahles; Linda R Bressler; Camilo E Fadul; Chetaye Knox; Nguyet Le-Lindqwister; Paul B Gilman; Charles L Shapiro Journal: JAMA Date: 2013-04-03 Impact factor: 56.272
Authors: Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel Journal: Oncologist Date: 2019-10-14
Authors: Tito R Mendoza; Xin Shelley Wang; Loretta A Williams; Qiuling Shi; Elisabeth G Vichaya; Patrick M Dougherty; Sheeba K Thomas; Emre Yucel; Christel C Bastida; Jeanie F Woodruff; Charles S Cleeland Journal: J Pain Date: 2015-07-22 Impact factor: 5.820
Authors: Ellen M Lavoie Smith; Lang Li; Raymond J Hutchinson; Richard Ho; W Bryan Burnette; Elizabeth Wells; Celia Bridges; Jamie Renbarger Journal: Cancer Nurs Date: 2013 Sep-Oct Impact factor: 2.592